home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

New Tool Predicts Cancer Outcome

 
  January, 13 2002 7:00
your information resource in human molecular genetics
 
     
Using the latest tools for genomic analysis, researchers at the Whitehead Institute for Biomedical Research in Massachusetts have been able to distinguish which of a group of cancer patients will be cured and which will die (Nature Medicine, Vol. 8, No. 1, p. 68, 01 Jan 02). This form of diagnostic analysis is the first in a new line of techniques based on knowledge from the human genome that will revolutionize healthcare.

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid cancer in adults, and over 50% of patients die from the cancer. Currently, the outcome of many cancers is predicted from assessment of the clinical status of the cancer-tumor size, age of patient, etc. However, gene activities that determine the biological behavior of a tumor are more likely to reflect its aggressiveness.

Todd Golub and colleagues used a technology called microarray analysis, which allows the genomic activity of a tissue to be analyzed in terms of its gene expression pattern. The scientists analyzed the expression of 6,817 genes in tissues from patients with DLBCL and found that, based on their gene expression profile, they could be divided into two groups with 5 year survival rates of 70% and 12%. Further determinations were made on those who were more likely to die or be cured.

Laura Van't Veer and Daphne de Jong discuss the technique in an accompanying News and Views article (p. 13). Based on such microarray analysis, some patients could be selected for different forms of chemotherapy.

Author contact:

Dr. Todd R. Golub
Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology Center for Genome Research
Cambridge, Massachusetts
Tel: +1 617 632 4903
Fax: +1 617 632 4850
Email: golub@genome.wi.mit.edu

Dr. Laura J. Van't Veer
The Netherlands Cancer Institute
Antoni van Leeuwenhoek Hospital
Amsterdam,
The Netherlands
Tel: +31 20 5122754
Fax: +31 20 5122759
Email lveer@nki.nl

(C) Nature Medicine press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.